Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ShenSongYangXin Capsules for Prevention of Sudden Cardiac Death in Organic Heart Disease with Ventricular Arrhythmia
ChiCTR2400084214Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of shensong yangxin capsule in sudden cardiac death (SCD), coronary arteriosclerosis, dilated cardiomyopathy (DCM) and 8 more (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Composite events of sudden cardiac death. Planned start May 2024; status: not yet recruiting.
02
Drugs
shensong yangxin capsule
03
Conditions
sudden cardiac death (SCD)coronary arteriosclerosisdilated cardiomyopathy (DCM)hypertrophic cardiomyopathy (HCM)hypertensive heart disease
Beyond the preview
Go deeper on ChiCTR2400084214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084214.